Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CollPlant Biotechnologies (CLGN) EPS (Weighted Average and Diluted) (2019 - 2025)

CollPlant Biotechnologies filings provide 7 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.23 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 29.99% to -$0.23 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.23, a 29.99% increase, with the full-year FY2025 number at -$0.94, up 35.17% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.23 in Q4 2025 for CollPlant Biotechnologies, down from $0.28 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.88 in Q1 2021 to a low of -$0.39 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.3 (2021), compared with a mean of $0.13.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 314.29% in 2021 and later plummeted 230.0% in 2022.
  • CollPlant Biotechnologies' EPS (Weighted Average and Diluted) stood at -$0.3 in 2021, then crashed by 30.0% to -$0.39 in 2022, then rose by 1.08% to -$0.39 in 2023, then rose by 14.42% to -$0.33 in 2024, then grew by 29.99% to -$0.23 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.23 (Q4 2025), $0.28 (Q2 2025), and -$0.33 (Q4 2024) per Business Quant data.